# Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

> **NCT04538378** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 4 (actual)

## Conditions studied

- EGFR-Mutated Non-Small-Cell Lung Carcinoma
- Small Cell/Neuroendocrine

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Durvalumab
- **DIAGNOSTIC_TEST:** EKG
- **PROCEDURE:** Tumor biopsy
- **DIAGNOSTIC_TEST:** CT chest, abdomen and pelvis
- **DIAGNOSTIC_TEST:** MRI chest, abdomen and pelvis

## Key facts

- **NCT ID:** NCT04538378
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-07
- **Primary completion:** 2023-03-22
- **Final completion:** 2024-02-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Closed due to slow accrual.
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04538378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04538378, "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04538378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*